SHOULD GONADOTROPIN RELEASING HORMONE ANALOGUE BE ADMINISTERED TO PREVENT PREMATURE OVARIAN FAILURE IN YOUNG WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS ON CYCLOPHOSPHAMIDE THERAPY?

Background: Accelerated atherosclerosis is widely present in patients with systemic lupus erythematosus. Objective: The aim of this review is to analyze the relationship between systemic lupus erythematosus and cardiovascular diseases, with the emphasis on acute myocardial infarction. Results: Various molecular mechanisms triggered by infection/inflammation are responsible for endothelial dysfunction and development of atherosclerosis at an earlier age. Contributing factor is the cumulative effect of traditional cardiovascular risk factors interaction with disease related characteristics. Myocardial infarction rates are 2- to 10-fold higher compared to the general population. Young women have the highest relative risk, however, men carry at least 3- fold higher risk than women. Coronary involvement varies from normal coronary artery with thrombosis, coronary microartery vasculitis, coronary arteritis, and coronary atherosclerosis. Typical clinical presentation is observed in men and older women, while atypical is more frequent in young women. Treatment is guided by the underlying mechanism, engaging invasive procedures alone, or accompanied with immunosuppressive and/or antiinflammatory therapy. There are significant gender differences in pathophysiology and clinical presentation. However, they receive the same therapeutic treatments. Conclusion: Systemic lupus erythematosus is a major contributor to atherosclerotic and non-atherosclerotic mechanisms involved in the development of myocardial infarction, which should be taken into account during therapeutic treatment. Although Systemic lupus erythematosus per se is a “female” disease, males are at increased cardiovascular risk and worse outcome. Method: We conducted a literature review through PubMed and Cochrane, using key words: SLE, atherosclerosis, atherothrombosis, coronary artery disease, myocardial infarction, prognosis, sex specifics.

Download Full-text

AB0074 Pulse methylprednisolone and cyclophosphamide therapy in three systemic lupus erythematosus patients with bronchiolitis obliterans organising pneumonia as the initial manifestation

10.1136/annrheumdis-2001.119 ◽

2001 ◽

Author(s):

JC Tseng ◽

HH Cheng ◽

RJ Hu ◽

LY Lu

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Bronchiolitis Obliterans ◽

Systemic Lupus ◽

Initial Manifestation ◽

Pulse Methylprednisolone ◽

Cyclophosphamide Therapy

Download Full-text

Limbic encephalitis in a patient with systemic lupus erythematosus successfully treated with high-dose glucocorticoids and intravenous cyclophosphamide therapy: the potential pathogenicity of anti-glutamate receptor antibodies

Modern Rheumatology Case Reports ◽

10.1080/24725625.2021.1876340 ◽

2021 ◽

pp. 1-6

Author(s):

Haruka Tsuchiya ◽

Yukiko Iwasaki ◽

Hirofumi Shoda ◽

Yukitoshi Takahashi ◽

Keishi Fujio

Keyword(s):

Systemic Lupus Erythematosus ◽

Glutamate Receptor ◽

Lupus Erythematosus ◽

Limbic Encephalitis ◽

High Dose ◽

Systemic Lupus ◽

Intravenous Cyclophosphamide ◽

Cyclophosphamide Therapy ◽

Potential Pathogenicity ◽

Receptor Antibodies

Download Full-text

Short-term effects of gonadotropin-releasing hormone analogue treatment on leptin, ghrelin and peptide YY in girls with central precocious puberty

Journal of Pediatric Endocrinology and Metabolism ◽

10.1515/jpem-2020-0470 ◽

2021 ◽

Vol 34 (4) ◽

pp. 479-484

Author(s):

Piyathida Wijarn ◽

Preamrudee Poomthavorn ◽

Patcharin Khlairit ◽

Sarunyu Pongratanakul ◽

Laor Chailurkit ◽

...

Keyword(s):

Precocious Puberty ◽

Peptide Yy ◽

Central Precocious Puberty ◽

Gonadotropin Releasing Hormone ◽

Hormone Analogue ◽

Short Term ◽

Serum Leptin ◽

Releasing Hormone ◽

Gonadotropin Releasing Hormone Analogue ◽

Before And After

Abstract Objectives To determine appetite-regulating hormone levels in girls with central precocious puberty (CPP) before and after 20 weeks of gonadotropin-releasing hormone analogue (GnRH-A) treatment. Methods Eighteen newly diagnosed CPP girls were enrolled. Body composition measured by bioelectrical impedance analysis and GnRH-A test were performed with fasting serum leptin, ghrelin and peptide YY (PYY) measurements at baseline (before) and after 20 weeks of GnRH-A treatment. Results Following GnRH-A treatment, all patients had prepubertal gonadotropin and estradiol levels. Mean (SD) fat mass index (FMI) was significantly increased from 4.5 (1.7) to 5.0 (1.8) kg/m2 after treatment. Also, median (IQR) serum leptin level was significantly increased from 6.9 (4.2–8.6) to 7.4 (5.3–13.1) ng/mL. FMI had a positive correlation with serum leptin level (r=0.64, p=0.004). In contrast, no significant changes of serum ghrelin and PYY levels were observed. Conclusions Decreased estrogen following short-term GnRH-A treatment in CPP girls may cause an increase in appetite and consequently an elevation of FMI. Increased serum leptin may be a result of having increased FMI secondary to an increase in appetite.

Download Full-text